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Abstract
Background: The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been
established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from
routine practice is needed to complement the data from the pivotal trials.
Methods: OPTIPARK (NCT02847442) was a prospective, open-label, single-arm trial conducted in Germany and the UK
under clinical practice conditions. Patients with Parkinson’s disease and motor fluctuations were treated with
opicapone 50mg for 3 (Germany) or 6 (UK) months in addition to their current levodopa and other antiparkinsonian
treatments. The primary endpoint was the Clinician’s Global Impression of Change (CGI-C) after 3 months. Secondary
assessments included Patient Global Impressions of Change (PGI-C), the Unified Parkinson’s Disease Rating Scale
(UPDRS), Parkinson’s Disease Questionnaire (PDQ-8), and the Non-Motor Symptoms Scale (NMSS). Safety assessments
included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
Results: Of the 506 patients enrolled, 495 (97.8%) took at least one dose of opicapone. Of these, 393 (79.4%) patients
completed 3months of treatment. Overall, 71.3 and 76.9% of patients experienced any improvement on CGI-C and
PGI-C after 3 months, respectively (full analysis set). At 6 months, for UK subgroup only (n = 95), 85.3% of patients were
judged by investigators as improved since commencing treatment. UPDRS scores at 3 months showed statistically
significant improvements in activities of daily living during OFF (mean ± SD change from baseline: − 3.0 ± 4.6, p <
0.0001) and motor scores during ON (− 4.6 ± 8.1, p < 0.0001). The mean ± SD improvements of − 3.4 ± 12.8 points for
PDQ-8 and -6.8 ± 19.7 points for NMSS were statistically significant versus baseline (both p < 0.0001). Most of TEAEs
(94.8% of events) were of mild or moderate intensity. TEAEs considered to be at least possibly related to opicapone
were reported for 45.1% of patients, with dyskinesia (11.5%) and dry mouth (6.5%) being the most frequently reported.
Serious TEAEs considered at least possibly related to opicapone were reported for 1.4% of patients.
Conclusions: Opicapone 50mg was effective and generally well-tolerated in PD patients with motor fluctuations
treated in clinical practice.
Trial registration: Registered in July 2016 at clinicaltrials.gov (NCT02847442).
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Introduction
The success of levodopa used together with other anti-
parkinsonian drug classes means that most patients liv-
ing with Parkinson’s disease (PD) enjoy a good quality of
life for many years [1, 2]. Nevertheless, the long term
therapeutic response is marred in many by the emer-
gence of disabling fluctuations and dyskinesias [3, 4] that
lead to a reduced quality of life and motor handicap [2,
5]. Wearing-off results from levodopa’s short duration
response which reflects the amino acid’s short half-life
(~ 60–90 min) [6]. Over time, patients will experience
more and more hours per day in a disabling OFF-state
and some will develop intrusive and adventitious invol-
untary movements [7].
Current treatment guidelines consider adjunctive treat-
ment with catechol-O-methyltransferase (COMT) inhibi-
tors, dopamine agonists and monoamine oxidase type B
(MAO-B) inhibitors, as efficacious to reduce OFF time in
patients treated with levodopa/dopa decarboxylase inhibi-
tor (DDCI) therapy [8–10]. In routine practice, many phy-
sicians will also consider various formulations of levodopa
(e.g. controlled-release and extended-release preparations)
as well as dosing manipulations to increase the dose and/
or dosing frequency of levodopa. COMT inhibitors have
been an established first-line strategy to manage motor
fluctuations for over 25 years [11–14], and are the only ad-
junct class to directly address the peak-trough variations
in plasma levodopa levels that clinically manifest as
wearing-off fluctuations [15]. The third generation COMT
inhibitor – opicapone (Ongentys®, BIAL-Portela & Cª, S.A.
Portugal) – has been approved in Europe since 2016 as
adjunct therapy to preparations of levodopa/DDCI for
end-of-dose motor fluctuations. Based on rational drug
design, opicapone was specifically developed to reduce the
risk of toxicity and improve peripheral tissue selectivity
[16]. In one pharmacokinetic study, opicapone (50mg
once daily) significantly increased levodopa bioavailability
compared with both placebo and entacapone (200mg
TID) by increasing substantially the trough plasma levels
and each dose systemic exposure time (half-life) by at least
1 h [17]. Phase III studies have established that treatment
with opicapone 50mg once daily reduces daily OFF-time,
without significantly increasing ON-time with trouble-
some dyskinesia versus placebo, and most patients show
an improvement in the Clinician’s Global Impression of
Change (CGI-C) [18, 19].
While placebo-controlled trials remain the gold stand-
ard in assessing response to a therapeutic intervention,
alone they do not provide sufficient information of clin-
ical effectiveness and safety. Many regulators and payers
now encourage the supplementation of randomized con-
trolled trials with other forms of evidence, such as ‘real-
world’ studies [20, 21]. The aim of this study was to
evaluate the change in the patient’s perception about
his/her global PD condition (as assessed by CGI-C) after




This was a prospective open-label, single-arm, multicen-
ter trial evaluating opicapone 50 mg effectiveness in
levodopa-treated PD patients experiencing motor fluctu-
ations. The study was conducted from November 2016
to July 2018 at 68 specialist neurology centers in
Germany and the United Kingdom (UK). Institutional
review boards at the participating sites approved the
protocol and the trial was conducted in accordance with
the Declaration of Helsinki and International Conference
on Harmonization Good Clinical Practice Guidelines.
All patients provided written informed consent; the
study was registered at EudraCT (2016–002391-27) and
clinicaltrials.gov (NCT02847442).
Study population
Men and women (≥30 years) with idiopathic PD [22] were
eligible if they reported symptoms of motor fluctuations
as identified by at least one symptom on the 9-Symptom
Wearing-off Questionnaire (WOQ-9) [23]. They also had
to be Hoehn and Yahr stages I-IV (during ON) and
treated with 3–7 daily doses of levodopa/DDCI. Key ex-
clusion criteria were atypical parkinsonism, severe unpre-
dictable OFF periods (investigator judgment) and severe
hepatic impairment (Child-Pugh Class C). Patients previ-
ously or currently treated with tolcapone and/or opica-
pone were also excluded from the study, as were patients
treated with MAO-A and MAO-B inhibitors other than
those for the treatment of PD [i.e. selegiline (≤10mg/day
in oral formulation or ≤ 1.25mg/day in buccal formula-
tion), rasagiline (≤1mg/day) or safinamide (≤100mg/
day)]. Patients treated with levodopa/DDCI/entacapone
before trial entry were to discontinue entacapone at the
baseline visit and switch to a levodopa/DDCI formulation.
Likewise, separate entacapone was to be discontinued by
the baseline visit at the latest.
Study design
Patients received opicapone 50mg capsules once-daily at
bedtime, at least 1 hour before or after the last daily
dose of levodopa/DDCI. The total duration of treatment
was 6 months in UK sites and 3months in German sites.
The longer duration of study in the UK was to provide
data for economic modelling which will be reported
elsewhere. Investigators were free to adjust total daily
levodopa/DDCI doses according to individual need after
the baseline visit. At study end, patients could be
prescribed with further opicapone treatment according
to local standard practice.
Reichmann et al. Translational Neurodegeneration             (2020) 9:9 Page 2 of 9
Endpoints were assessed at baseline, 1 month and 3
months or at any early discontinuation visit, and patients
in the UK were also assessed at 6 months. Best efforts
were made to have the same investigator/rater per pa-
tient throughout the study. The primary outcome was
the CGI-C (7 point scale, from very much improved to
very much worse), which assessed the patient’s percep-
tion about his/her global PD condition after 3 months of
treatment with opicapone 50 mg; the same rater assessed
CGI-C throughout the study and before the patient
made his/her own assessment. Secondary assessments
included the Patient’s Global Impression of Change
(PGI-C), WOQ-9 assessments, the Unified Parkinson’s
Disease Rating Scale (UPDRS) sections I-IV [24], the
Parkinson’s Disease Questionnaire (PDQ-8) [25], the
Non-motor Symptoms Scale (NMSS) [26] and change
from baseline in total daily levodopa dose and dosing
frequency. Treatment compliance was calculated based
on the numbers of dispensed and returned opicapone
capsules and treatment duration excluding interruptions
to study medication.
Safety was assessed through reporting of treatment
emergent adverse events (TEAEs) as well as vital signs
and physical and neurological examinations. Prespecified
subgroup analyses also evaluated change from baseline
in levodopa total daily dose in patients who reported
dopaminergic adverse events (i.e. dyskinesia, nausea,
vomiting, orthostatic hypotension, any hallucination,
illusion, delusion or disturbance in attention).
Statistical analysis
No sample size estimation was performed for this open-
label study. The safety population included all patients
who received ≥1 dose of opicapone. Effectiveness was
assessed in the full analysis set which included all patients
in the safety population who had ≥1 CGI-C recorded
post-baseline. Analyses were primarily descriptive; missing
values for the primary outcome measure (CGI-C) at Visit
4 was imputed using the last observation carried forward
method. For UPDRS II (at ON and OFF), UPDRS III (at
ON), UPDRS II plus III (at ON), PDQ-8 and NMSS
(including each domain) the means of changes from
baseline were analyzed using Student’s t-test.
In addition, subgroup analyses for the primary end-
point were performed by age (above vs. below the base-
line mean age), baseline use of dopamine agonists and
dopamine agonists plus MAO-B inhibitors (yes/no).
Results
Patient disposition and baseline characteristics
Five-hundred and six patients were enrolled at 68 cen-
ters across Germany and the UK. Of these, 495 (97.8%)
took at least one dose of opicapone (safety set) and 477
(94.3%) patients had at least one post-baseline CGI-C as-
sessment and were included in the full analysis set
(Fig. 1). A total of 109 (21.5%) patients prematurely ter-
minated the trial and stopped treatment with opicapone;
84 patients (17.0%) withdrew due to a TEAE (including
13.3% [n = 66] due to an at least possibly related TEAE)
Fig. 1 Patient disposition
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while three (0.6%) withdrew because of lack of efficacy.
A high percentage of patients (457/495; 92.3%) complied
with ≥80% of doses. The mean ± SD treatment compli-
ance was 99.2 ± 8.14%. Of the 386 patients who com-
pleted the trial, 332 patients (69.9%) continued to
receive opicapone by prescription.
Baseline characteristics are provided in Table 1. The
study population was comprised of white Caucasian
patients with a mean ± SD age of 67.7 ± 8.98 years, a
mean ± SD time since diagnosis of 102.1 ± 59.6 months
and a mean ± SD duration of motor fluctuations of
30.1 ± 38.0 months. The majority of patients (78.8%)
were on another levodopa adjunct medication: the most
common reported adjunct medications were rasagiline
(27.5%), pramipexole (24.8%) and ropinirole (22.4%).
Clinician and patient global impressions of change
After 3 months of treatment with opicapone 50 mg, the
majority of patients (71.3%) showed clinical improve-
ment as judged by the investigators (CGI-C), with 43%
reported as much or very much improved (Fig. 2a).
Similar improvements had already been observed at the
earlier 1month timepoint, where 75.8% of patients were
judged as improved, 16.9% as having ‘no change’ and 6.6%
as having worsened. For those UK patients (n = 95) who
were also assessed at 6months, 85.3% were judged as im-
proved since commencing treatment (8.5% very much im-
proved and 49.4% much improved) while 8.5% were
judged as showing ‘no change’ and 6.6% as having wors-
ened. Patients self-rated levels of improvement (PGI-C)
were consistent with primary results, with the majority of
patients (76.9%) reporting an improvement after 3months
of treatment with opicapone 50mg (Fig. 2b). For the sub-
group of UK patients also assessed at 6 months (n = 94),
79.8% self-reported an improvement, 12.8% reported no
change and 7.5% reported worsening.
Subgroup analyses for the primary efficacy endpoint
(CGI-C at Month 3) confirmed that improvements were
generally seen regardless of age or concomitant use of
dopamine agonists with or without MAO-B inhibitors at
baseline (Supplementary Table 1, Additional file 1).
Presence of symptoms as assessed by the WOQ-9
The proportions of patients reporting the overall pre-
sence of individual symptoms on the WOQ-9 decreased
from baseline to 3 months (Fig. 3).
Rating scale outcomes
Assessments of UPDRS scores after 3months of opicapone
treatment showed stability of mentation, behavior and
mood (Part I scores) and statistically significant improve-
ments in activities of daily living (ADL, Part II) during OFF,
motor scores (Part III) during ON and Total scores (Parts
II + III) during ON (Table 2). After 3months of treatment,
there was a mean reduction of 0.8 ± 1.9 points in UPDRS
IV scores (complications of therapy in the past week).
Improvements in both patient quality of life (as
assessed by the PDQ-8) and non-motor symptoms (as
assessed by the NMSS) were also observed after 3
months of treatment with opicapone. The mean ± SD
improvements of − 3.4 ± 12.8 points for PDQ-8 and
-6.8 ± 19.7 points for NMSS were statistically significant
versus baseline (both p < 0.0001). For the NMSS, most
Table 1 Baseline characteristics (safety set)
Category N = 495
Age (years); mean ± SD [range] 67.7 ± 8.98 [43–87]
Age categories; n (%)
≥30 to < 65 164 (33.1)
≥65 to < 85 325 (65.7)
≥85 6 (1.2)
Sex (M/F); n (%)a 315 (63.6)/179 (36.2)
Race: n (%)
White 495 (100.0)
Duration of Parkinson’s disease (months);
Mean ± SD 102.1 ± 59.60
Median [range] 89 [5–420]
Duration of motor fluctuations (months);
Mean ± SD 30.1 ± 37.97
Median [range] 15 [0–324]
Symptoms (WOQ-9 assessment); n (%)b
Tremor 299 (62.7)
Any slowness of movement 459 (96.2)
Mood changes 248 (52.0)
Any stiffness 393 (82.4)
Pain/aching 286 (60.0)
Reduced dexterity 433 (90.8)
Cloudy mind/slowness of thinking 223 (46.8)
Anxiety/panic attacks 119 (24.9)
Muscle cramping 288 (60.4)
Total levodopa daily dose (mg); mean ± SD 580.1 ± 289.1
Median [range] 525.0 [100–3750]








an = 1 missing, bassessed in the full analysis set, cpatients could take ≥ 1
adjunct therapy
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domains either remained stable or showed improvement
versus baseline (Supplementary Table 2, Additional
file 1). For example, sleep/fatigue showed a mean ± SD
change from baseline of − 1.3 ± 6.3 points (p < 0.0001) and
mood/cognition showed a mean ± SD change from
baseline of − 1.5 ± 6.82 points; p < 0.0001).
Levodopa dosing
After 3 months of treatment with opicapone, most
patients remained on the same total daily levodopa dose
(85% had no change in dose, 8.6% had a dose increase
and 5.7% had a dose decrease) and levodopa dosing fre-
quency (77.1% had no change, 8.4% had an increase and
Fig. 2 Global Impression of Change following 3months treatment with opicapone 50 mg (LOCF) (a) investigator rated (CGI-C, n = 477); (b) self-
rated by the patient (PGI-C, n = 393)
Fig. 3 Presence of PD symptoms as assessed on the WOQ-9 in patients who completed 3 months of study
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12.0% had a decrease in dosing frequency [data missing
for 2.4%]), resulting in an overall mean change of
approximately − 10mg/day. Similarly, for patients who
reported dopaminergic adverse events (full analysis set),
most patients (62.7%) remained on the same total daily
levodopa dose, 14.5% had a dose increase and 22.7% had
a dose decrease, resulting in an overall mean change of
− 26.6 mg/day.
Safety and tolerability
Overall, 371 (74.9%) patients experienced TEAEs, which
were mostly assessed as mild or moderate (Table 3).
Thirty four (6.9%) patients experienced serious TEAEs,
including one death due to endocarditis that was con-
sidered unrelated to treatment. A total of 223 (45.1%)
patients reported TEAEs that were assessed as at least
possibly related to treatment. In line with the pivotal
studies, the most frequent TEAEs (> 5%) considered
possibly treatment-related were dyskinesia (11.5%), dry
mouth (6.5%) and dizziness (4.8%); diarrhea was
reported in 3 (0,6%) patients. The frequency of at least
possibly related serious TEAEs was low: seven patients
(1.4%) had ≥1 of these events - anxiety, visual hallu-
cination, psychotic disorder, dizziness, hypertension,
hypotension, tachycardia and femoral neck fracture.
TEAEs led to premature termination in 84 (17.0%)
patients, but the precipitating events were diverse: the
most common TEAEs leading to withdrawal were nau-
sea (2.0%) and constipation (1.4%). Of these, 66 patients
(13.3%) had at least possibly treatment-related TEAEs
Table 2 Rating scale assessments
Rating scale
UPDRS Part I (mentation, behavior
and mood); mean ± SD
Baseline (n = 477) 2.3 ± 2.1
3 months (n = 393) 1.9 ± 1.9
Change from baseline (n = 393) − 0.3 ± 1.5
UPDRS Part II (ADL during OFF); mean ± SD
Baseline (n = 476) 17.1 ± 7.0
3 months (n = 391) 13.9 ± 6.8
Change from baseline (n = 391) − 3.0 ± 4.6
P value vs. baseline < 0.0001
UPDRS Part III (motor scores during ON);
mean ± SD
Baseline (n = 477) 26.5 ± 12.1
3 months (n = 393) 21.5 ± 11.0
Change from baseline (n = 393) − 4.6 ± 8.1
P value vs. baseline < 0.0001
UPDRS Total scores (Part II + III); mean ± SD
Baseline (n = 477) 37.5 ± 16.9
3 months (n = 393) 30.5 ± 15.2
Change from baseline (n = 393) − 6.4 ± 10.4
P value vs. baseline < 0.0001
UPDRS Part IV (complications of therapy);
mean ± SD
Baseline (n = 475) 5.2 ± 2.6
3 months (n = 391) 4.2 ± 2.4
Change from baseline (n = 391) − 0.8 ± 1.9
PDQ-8 Total Score; mean ± SD
Baseline (n = 476) 29.2 ± 16.4
3 months (n = 393) 25.2 ± 15.8
Change from baseline (n = 393) − 3.4 ± 12.8
P value vs. baseline < 0.0001
NMSS Score; mean ± SD
Baseline (n = 477) 44.6 ± 30.3
3 months (n = 393) 37.0 ± 26.7
Change from baseline (n = 393) − 6.8 ± 19.7
P value vs. baseline < 0.0001
NMSS Non-motor symptom scale, UPDRS Unified Parkinson’s Disease Rating
Scale, PDQ-8 Parkinson’s Disease Questionnaire
Table 3 Incidence of treatment emergent adverse events
TEAE Category N = 495
Any TEAE 371 (74.9)
Any treatment-relateda TEAE 223 (45.1)
Any serious TEAE 34 (6.9)
Any treatment-relateda serious TEAE 7 (1.4)
Any TEAE leading to discontinuation 84 (17.0)
Any treatment-relateda TEAE leading to
discontinuation
66 (13.3)
Any serious TEAE leading to discontinuation 8 (1.6)
Any TEAE leading to death 1 (0.2)
Treatment-related TEAEs (≥2% patients)
Dyskinesia 57 (11.5)













aTreatment-related TEAEs were any TEAEs that were considered at least
possibly related by the investigator and include the events with missing
relationship assessment
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leading to discontinuation. There were no relevant
changes in vital signs, physical and neurological exami-
nations throughout the study.
When analyzed by age (above vs. below the baseline
mean age), of the 371 patients that experienced TEAEs,
56.6% were from the older group (≥67.7 years old).
Patients older than 67.7 years old also accounted for the
highest proportion of those who discontinued due to a
TEAE (n = 57 of 84).
Discussion
Taken overall, the results of this large open-label study in
PD patients with motor fluctuations are the first to con-
firm the effectiveness, safety and tolerability of once daily
opicapone 50mg as used in routine clinical practice. The
majority of patients showed improvements in their per-
ception about global PD condition (≥70% as judged by cli-
nicians and the patients themselves) 3months after they
started treatment with opicapone 50mg. Treatment was
generally well-tolerated and adverse events were as ex-
pected for a dopaminergic therapy in patients with PD.
While randomized controlled studies are often criticized
as recruiting patients who might best meet study end-
points [27], this large study mirrored a clinical setting
population by allowing the inclusion of a broader popula-
tion of fluctuating PD patients, including patients with
Hoehn and Yahr Stage IV. It is of interest to note that
more patients were judged to have shown clinical im-
provement in this real life study than had been reported in
the pivotal trials (71.3% in this study vs. 59.6% in the com-
bined pivotal studies [28]). Even more notable was the
proportion of patients who were judged as much/very
much improved (43.0% in this study vs 25.2% in the com-
bined pivotal studies [28]). These judgements made by the
investigators were corroborated by the patients themselves
with 40.5% patients reporting they were much or very
much improved after 3months treatment with opicapone
50mg. Treatment with opicapone was also associated with
a small but significant improvement in overall quality of
life, as assessed using the PDQ-8. As also observed from
the pivotal studies [18, 19], there was a proportion of pa-
tients who did not respond well to adjunct therapy with
opicapone. Studies with entacapone have shown that the
response to COMT inhibition is modulated by the COMT
Val158Met polymorphism, with significantly enhanced
efficacy in patients with the COMT (HH) genotype [29].
The impact of the COMT genotype on the opicapone
response is unknown and merits further study.
Despite optimized anti-PD therapy (according to clini-
cian’s judgement) and the fact that most (78.8%) patients
were receiving levodopa plus another PD medication,
UPDRS motor and ADL scores significantly improved
(by 4.6 and 3.0 points, respectively) with opicapone as
adjunct therapy. These magnitudes of effects have been
reported to be clinically significant [30–32] and may
therefore indicate that treatment with opicapone, not
only increases ON time, but also improve the quality of
ON time. Non-motor symptoms are now acknowledged
as an important source of disability and contributor to
worse quality of life for people living with PD [33, 34].
In line with prior pivotal studies with opicapone, this
study also hinted towards an overall improvement in
non-motor symptoms [18, 19]. Some non-motor do-
mains are known to correlate with the motor OFF-state
and be dopa-responsive [35, 36] – with the implication
that optimization of the pharmacokinetic and pharmaco-
dynamic profile of levodopa with opicapone may be
beneficial in their management. As recently suggested by
Fabbri et al. [37], the effect of opicapone on various
non-motor symptoms merits further investigation.
Patients in this study maintained their levodopa dose for
up to 6months with sustained benefits in symptomatic con-
trol. Similar observations have also been seen in the 1-year-
long extensions of the pivotal studies [28, 37, 38]. This hints
at a possible long-term delay of need for levodopa increase.
Opicapone 50mg was generally well-tolerated, with
the majority of events reported as mild or moderate in
severity. While the most common reason for withdrawal
from the study was adverse events (17.0%), the causes
were diverse, with the most frequent (nausea) affecting
only 2% of patients (n = 10). While differences in study
duration and settings make comparisons difficult, similar
discontinuation rates due to AEs were reported in open-
label studies with entacapone [39, 40]. Although dyskin-
esia was reported as a TEAE in 11.5% of patients, only
five patients (1%) discontinued from the study due to
dyskinesia. The rate of serious TEAEs considered at least
possibly related to treatment was low (1.4%). One death
was reported; the 69 year old male patient died due to
severe endocarditis which was considered by the investi-
gator not to be related to the study medication.
Strengths of this study lie in its size, broad inclusion
criteria and routine practice setting. Although this study
permitted inclusion of a broad range of disease severities
(Hoehn and Yahr I-IV), we did not capture sufficient
data in this pragmatic study to analyze by subgroups.
Other weaknesses include those inherent to open-label
studies without placebo control, where both the clinician
and patient have expectations from treatment. Also, the
study was only conducted in two countries (UK and
Germany) and all patients were white Caucasian. We did
not study OFF and ON time since patient diaries carry
significant patient burden [41], which we wanted to
minimize in this routine practice study.
Conclusion
In routine clinical practice, once-daily opicapone 50 mg
as adjunct to levodopa-treated PD patients with motor
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fluctuations significantly improved patients’ perception
about their global PD condition. A similar impression
was reported by the clinicians. Opicapone was generally
well tolerated and significantly improved quality of life
and both motor and non-motor symptoms. These find-
ings confirm the clinical utility of opicapone 50mg as an
effective adjunct option for the management of motor
fluctuations in levodopa-treated PD.
Supplementary information
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1186/s40035-020-00187-1.
Additional file 1: Table S1. Subgroup analyses of the primary endpoint
(CGI-C at Month 3) by age and concomitant use of other adjunct
medications. Table S2. Change from baseline in NMSS domains.
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